ASSEMBLY BIOSCIENCES, INC. (ASMB) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-03-30

Key Insights

Assembly Biosciences has implemented a new 2026 Corporate Bonus Plan to motivate, retain and reward employees based on corporate and individual performance objectives.
The Compensation Committee has approved an increase in the bonus target for the CEO from 60% to 65% of his base salary, effective for fiscal year 2026.
The new bonus plan provides a framework for cash bonus awards that can range from 0 to 1.5 times a participant's bonus target, to be paid in the first quarter following the completion of the performance period.

Want the newest filings?

This analysis covers the filing from 2026-03-30. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-03-19

Assembly Biosciences reported its Q4 2025 and full-year 2025 financial results, providing investors with an update on the company's recent performance and operations.
The company's press release indicates continued progress in its pipeline of drug candidates, though specific details on clinical development and regulatory milestones were not provided.
Investors will be looking for more comprehensive updates on the company's key programs, as well as any changes to financial guidance or strategic plans, in the company's upcoming earnings call and regulatory filings.

Other reports for ASSEMBLY BIOSCIENCES, INC.

Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.